The advent of CAR T‐cell therapy has seen significant improvements in survival and is a potential cure for patients with advanced haematological malignancies
Cancer immunotherapy is a burgeoning field which, in the last decade, has produced unprecedented improvements in outcomes across a variety of advanced malignancies. The eventual translation of decades of research into clinically available immunotherapies stems from the expanded knowledge of the role that the immune system plays in preventing tumour initiation and progression as well as the mechanisms by which tumours learn to evade this immune surveillance.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Maus MV, Levine BL. Chimeric antigen receptor t‐cell therapy for the community oncologist. Oncologist 2016; 21: 608–617.
- 2. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev 2016; 30: 157–167.
- 3. Locke FL, Ghobadi A, Jacobson CA, et al. Long‐term safety and activity of axicabtagene ciloleucel in refractory large B‐cell lymphoma (ZUMA‐1): a single‐arm, multicentre, phase 1–2 trial. Lancet Oncol 2019; 20: 31–42.
- 4. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with b‐cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439–448.
- 5. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large b‐cell lymphoma. N Engl J Med 2018; 380: 45–56.
- 6. Neelapu S, Rossi J, Jacobson C. CD19‐loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post–axi‐cel [abstract]. Blood 2019; 134 (Suppl 1): 203.
- 7. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917–1923.
- 8. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 2016; 34: 4381–4389.
- 9. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B‐cell lymphoma: results from the international SCHOLAR‐1 study. Blood 2017; 130: 1800–1808.
- 10. Pasquini M, Locke F, Herrera A, et al. Post‐marketing use outcomes of an anti‐CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (axi‐cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US) [abstract]. Blood 2019; 134 (Suppl 1): 764.
- 11. Jaglowski S, Hu Z, Zhang Y, Kamdar M, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T‐cell therapy for adults with diffuse large B‐cell lymphoma (DLBCL): real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry [abstract]. Blood 2019; 134 (Suppl 1): 766.
- 12. Kuhnl A, Stewart O, Rowntree CI, Irvine DA. Real‐world data of high‐grade lymphoma patients treated with CD19 CAR‐T in England [abstract]. Blood 2019; 134 (Suppl 1): 767.
- 13. Wang M, Munoz J, Goy A, et al. KTE‐X19 CAR T‐Cell therapy in relapsed or refractory mantle‐cell lymphoma. N Engl J Med 2020; 382: 1331–1342.
- 14. Madduri D, Infante J, Rizvi S, et al. Results from CARTITUDE‐1: a phase 1b/2 study of JNJ‐4528, a CAR‐T cell therapy directed against B‐cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (r/r MM) [abstract]. Blood 2019; 134 (Suppl 1): 577.
Adrian Selim has received honoraria from Novartis. Constantine Tam was a principal investigator on the JULIET study sponsored by Novartis, and receives research funding from Janssen and AbbVie, and honoraria from Janssen, AbbVie, BeiGene, Novartis and Roche.